yourstate.us
Home / United States / 21 CFR
21 CFR 556.169

§ 556.169 Danofloxacin.

United States · 21 CFR — Food and Drugs · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 CFR 556.169, § 556.169 Danofloxacin, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87754
Permanent ID
ys:prov:87754@1
SHA-256
4e276e3c7dbf79f981dc06e2da0d37db55c3d5030e45f86da35b7ac88a6b5fe3

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Acceptable daily intake (ADI). The ADI for total residue of danofloxacin is 2.4 µg/kg of body weight per day. (b) Tolerances. The tolerances for danofloxacin (marker residue) are: (1) Cattle. (i) Liver (target tissue): 0.2 ppm. (ii) Muscle: 0.2 ppm. (2) [Reserved] (c) Related conditions of use. See § 522.522 of this chapter.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.